SeekingAlpha · Oct 27, 2026
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
CSL Limited (CSLLY) Shareholder/Analyst Call October 26, 2026 7:00 PM EDTCompany ParticipantsFiona Mead - Company Secretary & Head of Corporate...
CS
OTC · CSLLY
CSL Limited
Healthcare · Biotechnology
$34.99
Up+$0.35 (+1.00%)
Updated Nov 4, 2026, 7:16 PM
SID Score
6.3/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 116.24B
- P/E ratio
- 19.02
- Dividend yield
- 4.17%
- 52-week range
- — – —
- Volume
- 1.19K
- Avg. volume
- 161.07K
Price performance · CSLLY
CSLLY price history
1M range · 0 trading sessions · Daily adjusted prices
CSLLY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CSLLY news
The latest Smart Investors Daily articles mentioning CSLLY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CSLLY research
Overview
Company profile and research snapshot.
Company profile
CSL LTD SP/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $307.00
- Implied upside
- —
- Analysts
- 4
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | BELL POTTER SECURITIES | Hold | — |
| Sep 7, 2026 | CANACCORD GENUITY | Hold | — |
| Sep 2, 2026 | JEFFERIES | Hold | — |
| Aug 19, 2026 | MACQUARIE RESEARCH | Neutral | — |
| Jul 2, 2026 | BELL POTTER SECURITIES | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 24, 2026
CSL (ASX:CSL) After New CEO Pick Still Looks Undervalued In The Leading Narrative
CSL (ASX:CSL) has just confirmed a major leadership change, naming Deborah Waterhouse as incoming CEO and Managing Director from 1 February 2027, alongside news of a shareholder class action in Victoria. Recent trading shows CSL gaining momentum, with a 30-day share price return of 9.74% and a 90-day move of 72.21%, even though the 1-year total shareholder return has declined 5.01%. The CEO appointment and class action filing together appear to be reshaping how investors weigh future growth...
Yahoo · Oct 21, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO from February
Investing.com -- Australian biotechnology company CSL Ltd (ASX:CSL) has appointed Deborah Waterhouse, chief executive of GSK-controlled ViiV Healthcare, as its next chief executive officer, tasking the industry veteran with restoring growth, strengthening its drug pipeline and improving operational performance.
Yahoo · Oct 8, 2026
Haemonetics stock surges 17% on CSL Plasma supply deal update
Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
